Proactive case-finding and risk-stratification in people at risk of chronic liver disease in Greater Manchester: a cost-effectiveness analysis

Gabriel Rogers[1*] iD, Stephanie Landi[2,3] iD, Huw Purssell[2,3] iD, Tonia Momoh[1] iD, Sol Yates[1] iD, Oliver Street[2] iD, Karen Piper Hanley[2] iD, Neil Hanley[2,4,5] iD, Varinder Athwal[2,3] iD, Katherine Payne[1] iD

[1] Manchester Centre for Health Economics, Faculty of Medicine, Biology and Health, University of Manchester

[2] Faculty of Medicine, Biology and Health, University of Manchester

[3] Manchester University NHS Foundation Trust

[4] College of Medicine and Health, University of Birmingham

[5] University Hospitals Birmingham NHS Foundation Trust

[*] Correspondence to Gabriel Rogers, Manchester Centre for Health Economics, Jean McFarlane Building, University of Manchester, Oxford Road, Manchester. M13 9PL. United Kingdom. gabriel.rogers@manchester.ac.uk

ABSTRACT

Background: We urgently need innovative strategies to combat a growing epidemic of chronic liver disease (CLD). ID-LIVER was a collaborative project aiming to improve detection of reversible-stage CLD in a region with high prevalence of critical risk factors.

Objective: To determine the cost-effectiveness of ways to identify people with significant CLD, including proactive case-finding in the community (supplementing reactive referrals from primary care) and/or risk-stratification (using FIB-4 or ID-LIVER-ML -- a novel machine-learning risk-stratification tool).

Design: State-transition decision-analytic model estimating lifetime healthcare costs (2023/24 GBP) and quality-adjusted life-years (QALYs) associated with six alternative strategies for case-finding and risk-stratification. We simulated cohorts of people with alcohol-related liver disease (ARLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). We populated the model with data collected in ID-LIVER, supplemented by parameters from literature and routine data-sources. We estimated incremental cost-effectiveness and performed deterministic and probabilistic sensitivity analyses.

Results: Any case-identification strategy costing ≤3,300 GBP per person with significant CLD identified would meet English cost-effectiveness thresholds (20,000 GBP/QALY). In our decision-set, the cheapest strategy is to use FIB-4 in the reactive-only population. ID-LIVER-ML generates more population health at reasonable cost (10,490 GBP/QALY gained). Introducing proactive case-finding generates further health benefits, costing 12,952 GBP/QALY gained. Using ID-LIVER-ML in the proactive-and-reactive population has the highest probability of maximising cost-effectiveness, when valuing QALYs at 20,000 GBP.

Conclusion: Smart methods of case-finding and risk-stratification identify people with significant CLD in the community, and are likely to represent good value for money in England.

Funding: UK Research and Innovation (UKRI40896 & UKRI10057358).

1. **INTRODUCTION**

It almost seems to go without saying that early detection of chronic liver disease (CLD) will improve patient outcomes and deliver better value to health systems. A substantial number of people live with undiagnosed CLD, which often remains asymptomatic until it becomes life-threatening[1]. Identifying these cases earlier could improve health outcomes and reduce long-term healthcare costs. However, finding people who would benefit from a diagnosis of CLD while making efficient use of NHS resources is challenging. Early detection initiatives have costs and, without targeted approaches, hepatology services risk becoming overwhelmed by referrals of people who ultimately do not have clinically significant disease. While some local commissioners have established referral pathways from primary care, fewer have implemented proactive case-finding strategies for at-risk individuals in the community[2].

Around 90% of CLD mortality in England over the last two decades was lifestyle related, with the most common causes alcohol-related liver disease (ARLD) and metabolic-dysfunction-associated steatotic liver disease (MASLD)[3]. The North West has the highest prevalence of alcohol- and diet-related risk factors for CLD in England[4]. Integrated Diagnostics for Early Detection of Liver Disease (ID-LIVER) was a large, collaborative research project based in Greater Manchester, funded to unite universities, NHS trusts, and small and large commercial partners. It addressed critical gaps around improving the detection of CLD at reversible stages, moving diagnostics and initial management to community-based care, and enabling needs-based diagnostics and interventions[5]. One work-package focused on identifying people in the community at risk of CLD ('proactive case-finding'), using digital search-tools in routine primary-care data. People with one or more risk factor for ARLD or MASLD were invited to a community liver assessment clinic (CLAC) with a hepatologist and hepatology nurse, held in an accessible location (local healthcare facilities or a mobile screening van)[6]. In another work-package, the investigators used machine-learning algorithms to develop a risk-prediction tool identifying cases with a high probability of significant fibrosis (hereafter 'ID-LIVER-ML')[7]. Uniform data were collected for all participants – those in the proactive case-finding population attending a CLAC and routine referrals attending a hepatology outpatient clinic – including liver stiffness measurement (LSM) using vibration-controlled transient elastography. These data were used to train and validate the ID-LIVER-ML model, using LSM $\geq$ 8.0kPa – indicating high risk of significant fibrosis – as a reference standard.

In this study, we use data from these work-packages to evaluate the cost effectiveness of strategies incorporating one or both of proactive case-finding and enhanced risk-stratification (ID-LIVER-ML), compared with standard referral pathways.

2. METHODS

We developed a model-based cost-effectiveness analysis to evaluate the benefits, harms, and costs of different strategies to identifying patients with CLD in the community setting. The analysis conforms to the NICE reference case, adopting an NHS and personal social services perspective on costs[8]. This report follows the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (see *eAppendix 1*)[9].

2.1. Strategies evaluated

We evaluate two approaches to case-identification and three approaches to risk-stratification, combining factorially to represent six possible strategies (*Figure 1*).

FN = false negative; FP = false negative; ID-L-ML = ID-LIVER machine-learning risk-prediction model; TN = true negative; TP = true positive

Figure 1   Illustration of the six strategies evaluated, combining two approaches to case-identification and three approaches to risk-stratification

For case-identification, the 'reactive' approach represents the current pathway, where hepatology units passively receive referrals, primarily from GPs. The 'reactive+proactive' approach supplements routine referrals with case-finding in the community, as explored in ID-LIVER[5]. The three approaches to risk-stratification are: none (everyone referred receives secondary-care review); FIB-4 (limiting secondary-care review to people with a given score); and ID-LIVER-ML (referral only for people with a given probability of significant CLD).

2.2. Model structure

We use two independent but structurally identical decision-analytic models – one each for ARLD and MASLD – and weight results together as a final step. The models begin with decision-trees that apportion the cohorts into three categories: minimal fibrosis (equivalent to METAVIR F0/F1), significant fibrosis (F2/F3), and compensated cirrhosis (F4), further subdividing according to the proportion in each category the strategy in question identifies or misidentifies. Then, to simulate the natural and treated history of CLD, and thereby capture the impact of correct identification, we use state-transition (Markov) models; *Figure 2* provides a depiction of their structure. Cohorts enter the state-transition models from the terminal nodes of the decision-tree. Subsequent states reflect long-term consequences of CLD: decompensated cirrhosis (note that this state does not necessarily reflect people experiencing acute decompensating events; rather it represents people who have had at least one such episode), hepatocellular carcinoma (HCC), and death. We distinguish between early HCC (BCLC 0/A), late HCC (BCLC B/C), and HCC arising in a failing liver (BCLC D). Decompensated cirrhosis and HCC are subject to excess, liver-specific mortality; other-cause deaths can occur in any state. Diagnosis of significant fibrosis leads clinicians to recommend lifestyle interventions that may slow disease progression. Thus, people correctly diagnosed have a lower probability of progressing to subsequent states, and may even reverse their liver damage. We assume that regression is not possible from cirrhosis. Once people enter the decompensated cirrhosis state, their CLD becomes known, regardless of whether it was previously diagnosed. People developing HCC come to attention one year later.

We use an annual cycle length with half-cycle correction, and set the model's time-horizon so that all cohorts reach the age of 100. We apply a discount rate of 3.5% for costs and outcomes measured in quality-adjusted life years (QALYs).

Upper panel: Decision-tree showing how the model apportions cohorts according to (a) underlying level of fibrosis (minimal [F0/F1], significant [F2/F3], compensated cirrhosis [F4]), and (b) whether the strategy in question identifies people in each category. Note that the model needs to simulate reactive and proactive populations for all strategies, regardless of whether the strategy in question targets one or both populations (meaning reactive-only strategies have sensitivity of 0 and specificity of 1 in the proactive population, classifying all people as either true- or false-negatives).

Lower panel: Markov model simulating natural history of liver disease. Boxes show health-states. Arrows show possible transitions: dotted arrows show transitions that differ in probability between people with diagnosed and undiagnosed liver disease; dashed arrows show transitions where excess risk of death applies. Outlined block arrows identify states in which cohort initially enters model (as defined in terminal nodes of decision-tree).

BCLC = Barcelona Clinic Liver Cancer staging system; comp. = compensated; decomp. = decompensated; F0/1/2/3/4 = METAVIR fibrosis stage; HCC = hepatocellular carcinoma; LSM = liver stiffness measurement; p = probability

Figure 2   Model structure – decision-tree (identification probabilities) and Markov model (natural history)

2.3. Parameters

2.3.1. Baseline characteristics of cohorts

We base our simulated populations on data from ID-LIVER, comprising people with ARLD (n=286) and MASLD (n=850) identified via routine referral (n=840) or proactive case-finding (n=296). Starting age and sex depend on aetiology and stage of fibrosis; prevalence of each category of fibrosis depends on aetiology and mode of identification (*Table 1*).

Table 1   Summary of model parameters – baseline population

Parameter	Value (95% CI)	Probabilistic parameters	Source
Starting age (years)			
ARLD F0/1	55.4 (53.7, 57.1)	Normal: μ=55.40; σ=0.89	
ARLD F2/3	58.1 (55.4, 60.8)	Normal: μ=58.11; σ=1.37	
ARLD F4	58.6 (55.5, 61.8)	Normal: μ=58.63; σ=1.62	ID-LIVER cohort
MASLD F0/1	54.4 (53.3, 55.5)	Normal: μ=54.41; σ=0.55	
MASLD F2/3	57.1 (54.9, 59.2)	Normal: μ=57.05; σ=1.12	
MASLD F4	59.9 (55.8, 64.0)	Normal: μ=59.87; σ=2.09	
Sex (%male)			
ARLD F0/1	0.665 (0.595, 0.731)	Beta: α=121; β=61	
ARLD F2/3	0.557 (0.432, 0.679)	Beta: α=34; β=27	
ARLD F4	0.744 (0.605, 0.861)	Beta: α=32; β=11	ID-LIVER cohort
MASLD F0/1	0.452 (0.415, 0.489)	Beta: α=318; β=386	
MASLD F2/3	0.509 (0.418, 0.599)	Beta: α=59; β=57	
MASLD F4	0.600 (0.423, 0.765)	Beta: α=18; β=12	
Proportion of cases reactive			
ARLD	0.557 (0.509, 0.604)	Beta: α=235; β=187	ID-LIVER cohort
MASLD	0.631 (0.546, 0.711)	Beta: α=82; β=48	(financial yr 2022/23)
Proportion of cases with MASLD			
Reactive	0.731 (0.700, 0.760)	Beta: α=614; β=226	
Proactive	0.797 (0.750, 0.841)	Beta: α=236; β=60	ID-LIVER cohort
Weighted average	0.760		
Proportion with fibrosis at baseline			
Reactive			
ARLD			
F0/1 (LSM < 8kPa)	0.588 (0.524, 0.652)		
F2/3 (8kPa ≤ LSM < 15kPa)	0.230 (0.178, 0.287)	Dirichlet: α₁=133; α₂=52; α₃=41	ID-LIVER cohort
F4 (15kPa ≤ LSM)	0.181 (0.134, 0.234)		
MASLD			
F0/1 (LSM < 8kPa)	0.796 (0.764, 0.827)		
F2/3 (8kPa ≤ LSM < 15kPa)	0.158 (0.130, 0.188)	Dirichlet: α₁=489; α₂=97; α₃=28	ID-LIVER cohort
F4 (15kPa ≤ LSM)	0.046 (0.031, 0.063)		
Proactive			
ARLD			
F0/1 (LSM < 8kPa)	0.817 (0.710, 0.903)		
F2/3 (8kPa ≤ LSM < 15kPa)	0.150 (0.072, 0.250)	Dirichlet: α₁=49; α₂=9; α₃=2	ID-LIVER cohort
F4 (15kPa ≤ LSM)	0.033 (0.004, 0.091)		
MASLD			
F0/1 (LSM < 8kPa)	0.911 (0.872, 0.944)		
F2/3 (8kPa ≤ LSM < 15kPa)	0.081 (0.049, 0.118)	Dirichlet: α₁=215; α₂=19; α₃=2	ID-LIVER cohort
F4 (15kPa ≤ LSM)	0.008 (0.001, 0.023)		

ARLD = alcohol-related liver disease; F0/1/2/3/4 = METAVIR fibrosis stage; LSM = liver stiffness measurement; MASLD = metabolic-dysfunction-associated steatotic liver disease

2.3.2. Natural history of liver disease

To simulate fibrosis progression in MASLD, we use a study reporting sequential biopsies[10]. We derive analogous transition probabilities for ARLD from a multistate model we fitted to

patient-level data available in three studies exploring fibrosis progression in liver biopsies[11–13] (see *eAppendix2.1* for full details).

2.3.3. Benefits of early detection

Detecting CLD early leads to interventions that could slow or reverse disease progression. For MASLD, we use evidence from a UK study assessing impact of a very-low-calorie diet[14] (*eAppendix2.2* explains parameter derivation). We assume uptake is as observed in a trial assessing a similar intervention in people with diabetes[15]. Effectiveness evidence for ARLD-specific behavioural interventions comes from three retrospective cohort studies reporting association with time to decompensation[16–18]; uptake-level comes from a UK-based trial in people with alcohol-use disorder (but not necessarily ARLD)[19]. In our base case, we assume that these effects influence all progression transitions in the model; in a scenario analysis, we explore the impact of limiting the effect to the individual transitions that most closely reflect the effectiveness evidence.

A proportion of people with known compensated cirrhosis also benefits from HCC surveillance. We use UK evidence showing that the probability of finding HCC at an early stage is substantially higher in people undergoing surveillance, and project life expectancy accordingly[20]; *eAppendix2.3* provides details.

2.3.4. Effectiveness of ID-LIVER proactive case-finding

The effectiveness of ID-LIVER proactive case-finding is a simple function of the proportion of people with significant CLD successfully identified (that is, true-positives with LSM ≥ 8kPa), balanced against the group whose liver health-check did not reveal cause for immediate concern (false-positives). For strategies in which no case-finding takes place, these proportions become false-negatives and true-negatives, respectively.

Table 2 Summary of model parameters – natural history, accuracy of risk-stratification tools, and effectiveness of interventions

Parameter	Value (95% CI)	Probabilistic parameters	Source
Annual probability of fibrosis change			
ARLD			
F0/1→F0/1	0.946 (0.907, 0.978)	Bootstrapped output of multistate model; see *eAppendix2.1*	[11–13]
F0/1→F2/3	0.051 (0.021, 0.089)		
F0/1→CC	0.003 (0.001, 0.005)		
F2/3→F0/1	0.059 (0.021, 0.107)		
F2/3→F2/3	0.846 (0.774, 0.906)		
F2/3→CC	0.094 (0.049, 0.151)		
MASLD			
F0/1→F0/1	0.965 (0.955, 0.974)	Dirichlet (7.21yr): α_1=164; α_2=48	[10]
F0/1→F2/3	0.035 (0.026, 0.045)		
F2/3→F0/1	0.034 (0.022, 0.049)	Dirichlet (7.21yr): α_1=24; α_2=65; α_3=20	
F2/3→F2/3	0.938 (0.910, 0.961)		
F2/3→CC	0.028 (0.017, 0.041)		
CC → DC rate per year			
ARLD	0.073 (0.065, 0.082)	Lognorm: µ=−2.62; σ=0.06	[21]
MASLD	0.027 (0.016, 0.044)	Lognorm: µ=−3.62; σ=0.25	[22]
HCC rate per year			
ARLD no cirrhosis	0.000005	–	Assume proportional
ARLD with cirrhosis	0.0032 (0.0021, 0.0048)	Lognorm: µ=−5.759; σ=0.213	[23]
MASLD no cirrhosis	0.00005 (0.00004, 0.00006)	Lognorm: µ=−10.01; σ=0.11	[24]
MASLD with cirrhosis	0.023 (0.020, 0.026)	Lognorm: µ=−3.785; σ=0.066	[25–27]
Excess mortality: DC -v- gen. pop.			
ARLD SMR year 1	17.7 (14.5, 21.6)	Lognorm: µ=2.87; σ=0.10	[28]
ARLD SMR year 2 onwards	11.0 (9.4, 12.8)	Lognorm: µ=2.40; σ=0.08	
MASLD SMR year 1	13.70 (11.51, 16.31)	Lognorm: µ=2.62; σ=0.09	
MASLD SMR year 2 onwards	5.20 (4.38, 6.17)	Lognorm: µ=1.65; σ=0.09	
HCC survival (exponential)			
Ln(rate)	−1.80 (−1.96, −1.63)	Multivariate normal; see *eAppendix2.3*	[29]
Ln(HR) BCLC B/C -v- 0/A	1.36 (1.17, 1.54)		
Ln(HR) BCLC D -v- 0/A	2.44 (2.22, 2.66)		
Accuracy of risk-stratification tools			
Specificity (LSM < 8kPa)			
No risk-stratification	0.000	–	ID-LIVER holdout set
FIB-4 (1.3 threshold)	0.679 (0.628, 0.728)	Beta: α=226; β=107	
ID-LIVER-ML (0.4 threshold)	0.562 (0.508, 0.614)	Beta: α=187; β=146	
Sensitivity (8kPa ≤ LSM < 15kPa)			
No risk-stratification	1.000	–	
FIB-4 (1.3 threshold)	0.714 (0.556, 0.849)	Beta: α=25; β=10	
ID-LIVER-ML (0.4 threshold)	0.886 (0.763, 0.967)	Beta: α=31; β=4	
Sensitivity (15kPa ≤ LSM)			
No risk-stratification	1.000	–	
FIB-4 (1.3 threshold)	0.833 (0.587, 0.977)	Beta: α=10; β=2	
ID-LIVER-ML (0.4 threshold)	0.917 (0.715, 0.998)	Beta: α=11; β=1	
Effectiveness: lifestyle intervention			
MASLD			
OR for progression	0.212 (0.081, 0.555)	Lognorm: µ=−1.55; σ=0.49	[14]
Uptake of intervention	28.0% (25.8%, 30.3%)	Beta: α=423; β=1087	[15]
ARLD			
HR for progression	0.697 (0.479, 1.015)	Lognorm: µ=−0.36; σ=0.19	[16–18]
Uptake of intervention	29.3% (24.2%, 34.7%)	Beta: α=84; β=203	[19]
Effectiveness: HCC surveillance			
Prob of BCLC 0/A,no surveillance	0.177 (0.143, 0.214)	Beta: α=78; β=362	[20]
OR for BCLC 0/A, surv. -v- none	4.511 (3.271, 6.222)	Lognorm: µ=1.51; σ=0.16	
Surveillance uptake	67.7% (63.1%, 72.2%)	Beta: α=277; β=132	[29]

ARLD = alcohol-related liver disease; BCLC = Barcelona Clinic Liver Cancer stage; CC = compensated cirrhosis; DC = decompensated cirrhosis; F0/1/2/3/4 = METAVIR fibrosis stage; gen. pop. = general population; HCC = hepatocellular carcinoma; HR = hazard ratio; lognorm = lognormal; LSM = liver stiffness measurement; MASLD = metabolic-dysfunction-associated steatotic liver disease; OR = odds ratio; SMR = standardised mortality ratio

2.3.5. Diagnostic accuracy of risk-stratification tools

To estimate the diagnostic accuracy of FIB-4 and ID-LIVER-ML, we use the holdout dataset comprising 380 people from the ID-LIVER cohort whose data were not used in ID-LIVER-ML derivation. We split these individual data into fibrosis categories using LSM as a proxy measure: F0/F1 (LSM < 8.0kPa); F2/F3 (8.0kPa ≤ LSM < 15.0kPa); F4 (15.0kPa ≤ LSM). We can then observe the number of people in each fibrosis category testing positive at any given threshold of FIB-4 and ID-LIVER-ML, and use these data to define probabilities for use in the decision-tree. For the base case, we set thresholds of 1.3 for FIB-4 (as frequently cited[30,31]) and 0.4 for ID-LIVER-ML. It is not possible to distinguish ARLD and MASLD in the holdout dataset, so we assume that risk-stratification tools work equally well across both populations.

2.3.6. Resource-use and costs

Consistent with the study perspective, we account for resource-use associated with diagnosis and liver-related care only. This comprises four main elements: upfront costs (identification, risk-stratification, and initial assessment); ongoing, fibrosis-stage-specific hepatology costs; lifestyle interventions for a proportion of diagnosed people; and HCC treatment. All costs are in 2023/24 British pounds, inflated where necessary using Personal Social Services Research Unit (PSSRU) inflators [32]. Unit-costs mostly derive from NHS Cost Collection and PSSRU [32,33]. We provide full details in *eAppendix 3*; a summary follows.

We account for primary care appointments and tests for reactive referrals. People assessed in secondary care incur costs of hepatologist time and transient elastography (with nurse time to deliver). We assume hepatology units can deliver these in a 'one-stop' clinic, rather than requiring a series of appointments, as we have shown in ID-LIVER[6]. For proactive case-finding, we use estimates of £75 per person for identification (see *eAppendix3.1.2*) and £153 per person for CLAC attendance (*eAppendix3.1.2.2*). We assume that estimating FIB-4 / ID-LIVER-ML incurs no cost (noting that we have already accounted for the blood-tests that underpin them). We explore the possibility that ID-LIVER-ML may ultimately attract a licence-fee in threshold analysis.

For ongoing hepatology care, we only account for liver-related resource-use, so people with undiagnosed disease and those with F0/F1 fibrosis use no healthcare resources. We assume people with diagnosed F2/F3 fibrosis attend one hepatology outpatient appointment per year, including transient elastography and blood-tests. For people with diagnosed compensated

cirrhosis and anyone post-decompensation, we rely on costs estimated in NICE guideline NG50 (inflated to 2023/24 values). We add the costs of twice-yearly ultrasound and biochemistry for a proportion of people undergoing HCC surveillance.

For the proportion of people with MASLD accepting lifestyle intervention, we account for dietitian-time and use of meal-replacement products, directly reflecting the very-low-calorie diet we use for effectiveness estimates[14]. For ARLD, we assume a 12-appointment behavioural intervention, as recommended by NICE guideline CG115. See *eAppendix3.3*.

For HCC treatment, we mostly use costs estimated by Cullen *et al*.[34], although a more complex calculation is required for people receiving systemic anticancer therapy; this relies heavily on NICE technology appraisal TA551. *eAppendix3.4* gives details.

2.3.7. Health-related quality of life

We use EQ-5D-5L measurements from the ID-LIVER cohort, crosswalked to EQ-5D-3L values[35], to estimate health-related quality of life (HRQoL) in people with compensated CLD. The values distinguish between aetiology (ARLD -v- MASLD) and fibrosis stage (F0/F1 -v- F2/F3/F4). We translate absolute estimates into utility multipliers by dividing them by expected HRQoL for age- and sex-matched general population for each category[36]. In our base case, we assume that people retain the HRQoL associated with their baseline fibrosis-state, even if their fibrosis worsens or improves, until they experience decompensation or HCC diagnosis. This is because compensated CLD is largely asymptomatic, and we did not want to assume a causal relationship between liver pathology and HRQoL, when the association between the two is likely mediated by other factors (e.g. comorbidities; extent of obesity / harmful alcohol use). However, the lifestyle interventions that we simulate may also have an impact on these factors, so we explore the impact of allowing HRQoL to vary with fibrosis-state in a scenario analysis.

We calculate a pooled multiplier to reflect progression from compensated to decompensated cirrhosis from studies that report EQ-5D values for both states (*eAppendix4.1*). For HRQoL associated with HCC, we use evidence from a study examining the impact of early- and late-stage HCC diagnosis on HRQoL measured using SF-36[37], which we map to EQ-5D values[38].

Table 3   Summary of model parameters – costs and quality of life

Parameter	Value (95% CI)	Probabilistic parameters	Source
Costs			
Reactive referral (1° care)	£181 (£117, £259)	Gamma: α=25.00; β=7.26	See *eAppendix 3.1.1*
Reactive referral (2° care)	£296 (£191, £422)	Gamma: α=25.00; β=11.83	
Proactive case-finding (1° care)	£75 (£48, £107)	Gamma: α=25.00; β=2.20	See *eAppendix 3.1.2*
Proactive case-finding (2° care)	£153 (£99, £219)	Gamma: α=25.00; β=6.13	
Lifestyle intervention for MASLD	£1,208 (£782, £1,725)	Gamma: α=25.00; β=48.31	See *eAppendix 3.3*
Lifestyle intervention for ARLD	£862 (£558, £1,231)	Gamma: α=25.00; β=34.46	
Annual state-specific costs			
Undiagnosed liver disease	£0		
F0/1 known	£0		
F2/3 known	£309.96		
CC known	£475.71		Various, but particular reliance on NICE NG50, Cullen et al. (2023)[34], National cost collection 2023/24[33], and PSSRU 2023/24[39] See *eAppendix 3* for full details.
CC known + HCC surveillance	£596.85		
DC (MASLD)	£16,612.81		
DC (ARLD)	£24,169.21	See *eAppendix 3*	
HCC BCLC 0/A Yr1	£15,018.93		
HCC BCLC 0/A Yr2	£15,128.52		
HCC BCLC 0/A Yr3+	£4,801.62		
HCC BCLC B/C Yr1	£12,639.41		
HCC BCLC B/C Yr2	£13,008.73		
HCC BCLC B/C Yr3+	£4,801.62		
HCC BCLC D Yr1+	£21,739.80		
Quality of life: health-state utilities			
MASLD F0/1	0.773 (0.753, 0.793)	Normal: μ=0.773; σ=0.010	ID-LIVER cohort
Age- and sex-matched gen. pop.	0.855	See *eAppendix 4.1*	[36]
Multiplier -v- gen. pop.	0.904		
MASLD F2/3/4	0.658 (0.606, 0.710)	Normal: μ=0.658; σ=0.026	ID-LIVER cohort
Age- and sex-matched gen. pop.	0.845	See *eAppendix 4.1*	[36]
Multiplier -v- gen. pop.	0.779		
ARLD F0/1	0.750 (0.711, 0.790)	Normal: μ=0.750; σ=0.020	ID-LIVER cohort
Age- and sex-matched gen. pop.	0.857	See *eAppendix 4.1*	[36]
Multiplier -v- gen. pop.	0.876		
ARLD F2/3/4	0.667 (0.606, 0.728)	Normal: μ=0.667; σ=0.031	ID-LIVER cohort
Age- and sex-matched gen. pop.	0.847	See *eAppendix 4.1*	[36]
Multiplier -v- gen. pop.	0.787		
Multiplier, DC -v- other states	0.879 (0.824, 0.939)	Lognorm: μ=−0.128; σ=0.033	See *eAppendix 4.2*
Multiplier, early HCC -v- none	0.982	See *eAppendix 4.3*	[37]
Multiplier, late HCC -v- none	0.880		

ARLD = alcohol-related liver disease; BCLC = Barcelona Clinic Liver Cancer stage; CC = compensated cirrhosis; DC = decompensated cirrhosis; F0/1/2/3/4 = METAVIR fibrosis stage; gen. pop. = general population; HCC = hepatocellular carcinoma; lognorm = lognormal; MASLD = metabolic-dysfunction-associated steatotic liver disease

2.4. Implementation and sensitivity analysis

We built the model in Microsoft Excel. Probabilistic sensitivity analyses rely on 10,000 simulations, sampling all parameters from appropriate uncertainty distributions (mostly empirical; where unavailable, we assume standard error 20% of mean; see *Tables 1–3* and *eAppendices2–3*). We use bootstrapping to account for uncertainty in diagnostic accuracy inputs, taking a random sample of the ID-LIVER holdout population with replacement for each iteration of the model. We performed deterministic (one-way) sensitivity analyses to

explore individual parameters' influence on model outputs, and scenario analyses as noted above (see *eAppendix 9* for a list).

2.5. Patient and public involvement

ID-LIVER had a collaborative approach to patient and public involvement throughout all stages of project design, development and delivery. This was led by Vocal (wearevocal.org), a not-for-profit health research organisation, and involved regular input from two patient governance advisors with lived experiences of CLD risk factors. They attended work package meetings and participated in a monthly forum with the research team. The team actively consulted underserved community groups with CLD risk factors to improve communication and participation using tailored resources.

3. RESULTS

3.1. Natural history model

We start by estimating the impact early diagnosis of significant CLD – however achieved – has on expected lifetime costs and QALYs. *Figure 3* shows the difference in prognosis for true-positives and false-negatives in ARLD and MASLD populations (*eAppendix 3* gives separate graphs for each fibrosis state).

ARLD = alcohol-related liver disease; CC = compensated cirrhosis; DC = decompensated cirrhosis; F0/1/2/3/4 = METAVIR fibrosis stage; HCC = hepatocellular carcinoma; MASLD = metabolic-dysfunction-associated steatotic liver disease

Figure 3   State occupancy over time for people with significant fibrosis, according to aetiology (alcohol-related liver disease -v- metabolic-dysfunction-associated steatotic liver disease) and diagnosis status (false-negative -v- true-positive)

The most obvious impact of successful detection is regression of disease severity from F2/F3 to F0/F1 (i.e. the larger green area in true-positives), particularly in the MASLD population. There is also somewhat lower progression into the compensated cirrhosis, decompensated cirrhosis, and HCC health-states. The HCC health-state is inconspicuous because relatively

few people experience this event and most that do move quickly into the dead state. This is particularly true in ARLD, because incidence is lower and mortality associated with decompensated cirrhosis is higher in this population.

By aggregating costs and QALYs associated with predicted time in each state, we can estimate the impact of diagnosing versus not diagnosing CLD (see *Table e10*, in *eAppendix 6*). We find that, if we value QALYs at £20,000 each (NICE-recommended cost-effectiveness threshold), any programme that detects significant CLD at a cost of less than £3,300 per case would generate positive net benefit, compared with no detection. Using these data, we can estimate the cost effectiveness of any risk-stratification strategy for which we know sensitivity, specificity and upfront costs (see *Figure e3*, in *eAppendix 6*).

3.2. Cost effectiveness of case-finding and risk-stratification

Figure 4 shows incremental cost-effectiveness results for the six strategies our model simulates. The cheapest strategy is FIB-4-based triage for reactive referrals, because it is the approach that classifies most people – rightly or wrongly – as negative. Switching to risk-stratification with ID-LIVER-ML in the same population identifies more true-positives, generating 0.005 extra QALYs per person at an incremental cost of £52 (~£10,000 per QALY gained). Extending the population to include proactive case-finding generates a further 0.009 QALYs, at a cost of £123 per person (~£13,000 per QALY gained). We would gain most QALYs by combining reactive and proactive populations and applying no risk-stratification (under which strategy, hepatologists will see 100% of people who might be at risk). However, this is also the most expensive approach, and the incremental QALY-gain, compared with ID-LIVER-ML-based triage in the same population, would only be sufficient to counterbalance the incremental cost if we value QALYs at more than £28,000 each.

(1) Reactive (No triage)   (2) Reactive (FIB-4 @ 1.3)
(3) Reactive (ID-LIVER-ML @ 0.4)   (4) Reactive+Proactive (No triage)
(5) Reactive+Proactive (FIB-4 @ 1.3)   (6) Reactive+Proactive (ID-LIVER-ML @ 0.4)

Strategy		Absolute		Incremental			Net health benefit	
Case-finding	Risk-stratification (threshold)	Costs (£)	Effects (QALYs)	Costs (£)	Effects (QALYs)	ICER (£/QALY)	£20K/ QALY	£30K/ QALY
Reactive	FIB-4 (1.3)	£7,865	12.057				11.664	11.795
Reactive	ID-LIVER-ML (0.4)	£7,917	12.062	£52	0.005	£10,498	11.666	11.798
Reactive+Proactive	FIB-4 (1.3)	£7,970	12.065	£52	0.003	ext. dom.	11.666	11.799
Reactive	None	£8,015	12.066	£98	0.004	ext. dom.	11.665	11.798
Reactive+Proactive	ID-LIVER-ML (0.4)	£8,040	12.071	£123	0.009	£12,952	11.669	11.803
Reactive+Proactive	None	£8,179	12.076	£139	0.005	£28,753	11.667	11.804

Ext. dom. = extendedly dominated

Solid red line shows cost-effectiveness frontier. Dashed line in background shows iso-net-benefit gradient equal to £20,000 per QALY. If the line between any two points is shallower than this gradient, the option on the right (generating most QALYs) represents good value; if it is steeper, the option on the left is better value, assuming we value QALYs at £20,000 each.

Sub-table shows fully incremental analysis (i.e. incremental values reflect the comparison between each option and the next-cheapest non-dominated alternative).

All outcomes represent expected values per person within the whole at-risk population. All outcomes discounted at 3.5% per year.

Figure 4   Cost effectiveness of different approaches to case-finding and risk-stratification as assessed in ID-LIVER

3.3. Sensitivity analyses

Probabilistic sensitivity analysis outputs appear in *eAppendix 7*. If we value QALYs at £20,000 each, the probability that some form of risk-stratification with ID-LIVER-ML is optimal is around 0.7, and the probability that combining it with proactive case-finding provides greatest net benefit is around 0.5. FIB-4-led strategies have less than 0.25 probability of providing best value.

One-way sensitivity analysis (*eAppendix 8*) shows that we are fairly confident that ID-LIVER-ML is a better risk-stratification tool than FIB-4 in the reactive-only population (unless either lifestyle intervention is at the less effective bound of its 95% confidence interval) and, if we extend to the reactive+proactive population, ID-LIVER-ML is better than no risk-stratification. It is somewhat more uncertain whether extending from reactive-only referrals to proactive case-finding represents good value for money; effectiveness estimates for lifestyle interventions are the most obviously influential parameters (explored further in threshold analysis, below).

Scenario analyses (*eAppendix 9*) suggest that attenuating the benefit of diagnosis, by limiting the effect of lifestyle intervention to only one transition, means that the optimal strategy would be to see as few people as possible in secondary care (using FIB-4 in a reactive-only population). Conversely, diagnosis gets more valuable when we assume that HRQoL changes with fibrosis-stage; if we believe this, then it would probably be worth abandoning risk-stratification, and seeing everyone with risk factors in secondary care. When we derive costs of proactive case-finding from the ID-LIVER research budget, overall results do not change materially, though the comparison between ID-LIVER-ML in reactive-only and proactive-and-reactive settings becomes more finely balanced.

Threshold analysis (*eAppendix 10*) shows that lifestyle interventions would only have to be moderately less effective than our base-case estimate to make proactive case-finding bad value (odds ratio ≥0.45 instead of 0.21 for MASLD; hazard ratio ≥0.90 instead of 0.70 for ARLD). When evaluating cutoffs for risk-stratification tests, we find that none generates more net benefit than 0.4 for ID-LIVER-ML. For FIB-4, a cutoff of 0.75 – implying greater sensitivity but worse specificity than current conventions – provides most net benefit, but remains inferior to ID-LIVER-ML at its optimal cutoff. When we apply a cost to the ID-LIVER-ML model, we find that it remains good value for money at any cost ≤£42 per person.

4. DISCUSSION

4.1. Principal findings

Our study confirms the existence of a reservoir of people with undiagnosed CLD in the community, and shows that we can find some of them in targeted ways that represent good value for money. We also demonstrate that we can improve risk-stratification, both of these proactively identified people and the reactive referrals that remain hepatology services' stock-in-trade. Although FIB-4-based triage, as commonly used in the UK, is likely to reduce referrals and minimise secondary-care costs, it does so at the expense of ruling out some people with significant CLD. Our analysis suggests that ID-LIVER-ML can minimise such false-negatives, increasing population health at an incremental cost that reflects an effective use of NHS resources.

4.2. Strengths

Our study relies on a relatively large dataset, collected in a region with a particular need for diagnostic strategies that will identify people with significant CLD. It is an additional advantage that all participants received a test that is likely to classify their liver health accurately (transient elastography), in contrast to many other studies, in which people who are perceived to be at low risk receive no further investigation. We explicitly simulate the benefits of diagnosis, using best-available empirical data on the healthcare costs, health effects, and likely uptake of lifestyle interventions.

We are able to identify evidence-based, optimal thresholds for risk-stratification tools, based on expected lifetime population-level net benefit, which contrasts with the arbitrary cutoffs that are currently prevalent (e.g. using 1.3 for FIB-4 – which we find is suboptimal – is influenced by a US study that targeted a negative predictive value of 90% without any empirical foundation[31]).

Because of how we structured our analysis, its use is not limited to the approaches we explored in ID-LIVER: we could use it to estimate the cost effectiveness of any case-identification strategy for which we know sensitivity, specificity, and upfront costs.

Our sensitivity analyses enable us to stress-test the analysis and identify areas of greatest uncertainty; unsurprisingly, we find that the parameters with greatest influence on decision-

uncertainty are those reflecting the extent to which lifestyle interventions change the prognosis of people whose CLD has been identified.

4.3. Limitations

All diagnostic accuracy estimates in our study use vibration-controlled transient elastography as a proxy for true liver pathology. Investigators have shown high concordance between LSM and histology in both ARLD[40–42] and MASLD[43], but it is inevitable that some of the true-positives/false-negatives in our calculations do not have meaningful fibrosis and some of the true-negatives/false-positives do. However, for practical purposes, the distinction is moot: with biopsy becoming ever-rarer, clinicians are seldom directly guided by histology in practice. Moreover, liver biopsy is, itself, an imperfect test that may misclassify people owing to sampling error and/or intra- and inter-observer variability[44]. Therefore, we believe LSM represents as accurate an indicator of fibrosis-stage as is viable in present-day practice.

Our model simulates a one-time opportunity for identification, assuming that any case that is missed will only come to light when symptoms develop. On the one hand, this assumption may overstate value of case-finding, as people may still receive a diagnosis while asymptomatic via later healthcare contacts. On the other, it may understate value of case-finding, as people who are seen but – correctly or incorrectly – discharged may still benefit from lifestyle advice and may also be primed to heed future symptoms.

We have to model the natural history of undiagnosed disease which, by definition, is unobservable. The sequential biopsy studies we use probably provide a reasonable proxy, though any lifestyle modification participants adopted between biopsies may serve to bias true natural progression rates downwards. In this respect, it may not be a bad thing that our ARLD evidence[11–13] comes from a historical era (1970s–80s), during which behaviour-modification interventions were unusual. However, the studies also predate modern-day histopathological criteria, meaning we had to approximate the relationship between reported fibrosis findings and modelled states.

We do not simulate any pharmacological treatments that may slow progression of CLD. NICE's cirrhosis guideline (NG50) gives a weak ('consider') recommendation for beta-blockers for primary prevention of decompensation, based largely on a Spanish randomised trial[45]. Previous cost-effectiveness analyses[46,47] have assumed people with diagnosed CLD gain benefit from pioglitazone; there is some evidence this may be true[48], though we believe it is uncommonly prescribed for this indication in the UK (and is off-label when it is). There is

emerging evidence that GLP-1 receptor agonists may reduce LSMs and/or fibrosis[49,50]. Although none has a marketing authorisation explicitly covering MASLD, NICE currently recommends semaglutide for people with high BMI and 'at least 1 weight-related comorbidity' (TA875), as which MASLD would qualify. If any of these agents – or forthcoming MASLD-specific medicines such as resmetirom[51] – provide benefit at acceptable cost, and hepatologists enable access to them for at least some people with significant fibrosis, our analysis will underestimate the value for money with which each true-positive diagnosis is associated.

We chose not to model liver transplantation for people with decompensated cirrhosis (although it is an implicit part of the simulated pathway for early HCC). This outcome is rare for a member of our starting population, and associated with radically different prognosis and costs, making its influence on a decision-problem like this unpredictable.

4.4. Comparison with other research

There are three UK-focused analyses assessing referral pathways for people with suspected MASLD. Srivastava *et al*. assessed multiple risk-stratification algorithms relying on noninvasive tests including FIB-4, Enhanced Liver Fibrosis (ELF), and elastography for people in primary care with raised liver enzymes[52]. The authors find that noninvasive tests could increase true-positive referrals to secondary care while reducing false-positives, compared with unassisted GP decision-making (although their estimates of the accuracy of the latter are not based on any empirical data). They also find that identifying people with significant CLD yields net cost-savings, when accounting for prevention of downstream events. This finding contrasts with ours; however, there are multiple differences in methods and inputs. Critically, we specify, evidence, and account for the costs of a mechanism (lifestyle intervention) by which diagnosis may slow disease progression, where Srivastava *et al*. assume benefits without intervention costs. We also note that unit-costs of hepatology appointments have doubled in the time since their analysis. Finally, we note that Srivastava *et al*.'s preferred pathway excludes all people with FIB-4 <1.3; our findings suggest that a nontrivial proportion of such people have significant CLD.

Tanajewski *et al*. model a community risk-stratification pathway using transient elastography to assess people at risk of MASLD[47]. They find a 0.85 probability that the approach is associated with an ICER of £20,000 per QALY or better, compared with standard care. A shortcoming of the model is that it attempts to capture the benefit of diagnosis by assuming 100% of

people receive pharmacological treatment with pioglitazone, although this is uncommon in practice. Moreover, the effect-measure comes from a trial using a different drug (rosiglitazone) that has been withdrawn from the UK market (and, in any case, did not show a significant effect in the trial).

Crossan *et al*. assess non-invasive tests to triage secondary-care referrals for people with MASLD[53]. They find that all approaches deliver cost-savings, compared with indiscriminate referrals. They do not model consequences of correct/incorrect diagnoses (e.g. through expected lifetime QALYs). However, they suggest that greatest net benefit, across a range of hypothesised values indicating the relative importance of true- and false-positives, comes from a two-tiered approach using FIB-4 followed by ELF in indeterminate cases.

There are no cost-effectiveness analyses focusing on identifying ARLD in the UK. Asphaug *et al*. simulate various approaches to screening for ARLD in Denmark[54]. They model a hypothetical impact of diagnosis on drinking behaviour, assuming that CLD will only progress in people who continue to drink. They find that risk-stratification with ELF followed by elastography for positive cases is likely to be optimal in primary care, but an elastography-only approach is better in secondary care (although it is unclear why the elastography-only pathway generates fewer QALYs in primary care, when it has most true-positives in both scenarios).

We are not aware of any previous cost-effectiveness analyses looking at proactive case-finding in a broad community at risk for CLD, although one UK-focused cost-effectiveness analysis suggests it would be good value to screen for MASLD in people with type 2 diabetes[46].

4.5. Conclusions

Our economic evaluation suggests that early detection of ARLD and MASLD has the anticipated benefits for the person, and can be achieved in ways that represent good value for the system. Our conclusions depend importantly on the effectiveness of interventions to delay progression of CLD. However, any overestimate, in this domain, may be offset by other benefits that we cannot quantify (informal lifestyle advice; possible pharmacological interventions; spillover effects of liver-motivated behaviour-change for nonhepatic outcomes). We continue to undertake proactive case-finding in Greater Manchester, collecting similar data as in ID-LIVER. We intend to use these data to explore potential refinements to the approaches evaluated here. In particular, we aim to improve the specificity of initial digital searches in primary care records, assessing which (combinations of) high-level risk factors identify people at greatest risk of significant CLD.

5. END MATTER

5.1. Acknowledgements

We are very grateful for the input of our PPIE governance advisors (Ruth James and Catherine Lennon) and facilitator (Jenny Irvine at Vocal wearevocal.org). Thanks to British Liver Trust for advice on PPIE and subsequent input (Pamela Healy). At Manchester Centre for Health Economics, Anna Donten contributed to costing of the referral pathway and Ali Mahboub-Ahari helped to identify effectiveness and costing evidence for lifestyle interventions. We obtained valuable information to support our micro-costing of proactive case-finding from Northenden Group Practice (practice manager Allison Frith and GP Paul Wright). Mohamed Mostafa and Manish Patel at Jiva.ai generously provided data and insights relating to the ID-LIVER-ML model they developed.

5.2. Funding

This work was supported by the UK Research and Innovation [grant numbers UKRI40896 and UKRI10057358].

5.3. Declarations of interest

All authors declare they have no competing interests.

5.4. Contributions of authors (according to CRediT taxonomy)

	GR	SL	HP	TM	SY	OS	KPH	NH	VA	KP
Conceptualisation	Leading	Supporting							Supporting	Supporting
Data curation	Supporting	Leading	Leading						Supporting	
Formal analysis	Leading			Supporting	Supporting					Supporting
Funding acquisition						Supporting	Leading	Leading	Supporting	
Investigation		Leading	Leading						Supporting	
Methodology	Leading				Supporting					Supporting
Project administration						Leading				
Resources										
Software				Supporting						
Supervision	Supporting								Supporting	Leading
Validation		Supporting	Supporting			Supporting		Leading	Leading	
Visualisation	Leading									
Writing – original draft	Leading			Leading						
Writing – review & editing		Leading	Leading		Leading	Leading	Leading	Leading	Leading	Leading

Legend: Leading | Supporting

REFERENCES

1.   Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. The Lancet 2014;384(9958):1953–97.

2.   Jarvis H, Worsfold J, Hebditch V, Ryder S. Engagement with community liver disease management across the UK: a cross-sectional survey. BJGP Open [Internet] 2021 [cited 2025 Mar 12];5(5). Available from: https://bjgpopen.org/content/5/5/BJGPO.2021.0085

3.   Liver disease: applying All Our Health [Internet]. GOV.UK [cited 2024 Dec 13];Available from: https://www.gov.uk/government/publications/liver-disease-applying-all-our-health/liver-disease-applying-all-our-health

4.   Oztumer CA, Chaudhry RM, Alrubaiy L. Association between behavioural risk factors for chronic liver disease and transient elastography measurements across the UK: a cross-sectional study. BMJ Open Gastroenterol 2020;7(1):e000524.

5.   Bennett L, Purssell H, Street O, Piper Hanley K, Morling JR, Hanley NA, et al. Health Technology Adoption in Liver Disease: Innovative Use of Data Science Solutions for Early Disease Detection. Front Digit Health [Internet] 2022 [cited 2024 Dec 13];4. Available from: https://www.frontiersin.org/journals/digital-health/articles/10.3389/fdgth.2022.737729/full

6.   Landi S, Purssell H, Scott J, Street O, Piper Hanley K, Hanley NA, et al. A community diagnostic pathway to detect liver fibrosis in patients at-risk of Steatotic Liver Disease (SLD). Manuscript in preparation;

7.   Purssell H, Bennett L, Mostafa M, Hammersley R, Patel M, Scott J, et al. Improving the detection of clinically significant steatotic liver disease using a machine learning algorithm in a primary care population. Submitted for publication;

8.   National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual [PMG36] [Internet]. NICE; 2022 [cited 2024 Jan 19]. Available from: https://www.nice.org.uk/process/pmg36/

9.   Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med 2022;20(1):23.

10. Mcpherson S, Pais R, Valenti L, Schattenberg JM, Dufour JF, Tsochatzis E, et al. Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. J Hepatol 2017;66(1):S593.

11. Marbet UA, Bianchi L, Meury U, Stalder GA. Long-term histological evaluation of the natural history and prognostic factors of alcoholic liver disease. J Hepatol 1987;4(3):364–72.

12. Worner TM, Lieber CS. Perivenular Fibrosis as Precursor Lesion of Cirrhosis. JAMA 1985;254(5):627–30.

13. Nakano M, Worner TM, Lieber CS. Perivenular Fibrosis in Alcoholic Liver Injury: Ultrastructure and Histologic Progression. Gastroenterology 1982;83(4):777–85.

14. Scragg J, Avery L, Cassidy S, Taylor G, Haigh L, Boyle M, et al. Feasibility of a Very Low Calorie Diet to Achieve a Sustainable 10% Weight Loss in Patients With Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2020;11(9):e00231.

15. Taylor R, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohort. Diabetologia 2018;61(3):589–98.

16. Rogal S, Youk A, Zhang H, Gellad WF, Fine MJ, Good CB, et al. Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis. Hepatology 2020;71(6):2080.

17.   Vannier AGL, Przybyszewski EM, Shay J, Patel SJ, Schaefer E, Goodman RP, et al. Psychotherapy for Alcohol Use Disorder Is Associated With Reduced Risk of Incident Alcohol-Associated Liver Disease. Clin Gastroenterol Hepatol 2023;21(6):1571-1580.e7.

18.   Mellinger JL, Fernandez A, Shedden K, Winder GS, Fontana RJ, Volk ML, et al. Gender Disparities in Alcohol Use Disorder Treatment Among Privately Insured Patients with Alcohol-Associated Cirrhosis. Alcohol Clin Exp Res 2019;43(2):334–41.

19.   Crawford MJ, Patton R, Touquet R, Drummond C, Byford S, Barrett B, et al. Screening and referral for brief intervention of alcohol-misusing patients in an emergency department: a pragmatic randomised controlled trial. The Lancet 2004;364(9442):1334–9.

20.   Haq MI, Drake TM, Goh TL, Ahmed A, Forrest E, Barclay S, et al. Effect of Hepatocellular Carcinoma Surveillance Programmes on Overall Survival in a Mixed Cirrhotic UK Population: A Prospective, Longitudinal Cohort Study. J Clin Med 2021;10(13):2770.

21.   Fleming KM, Aithal GP, Card TR, West J. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Aliment Pharmacol Ther 2010;32(11–12):1343–50.

22.   Sanyal AJ, Natta MLV, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med 2021;385(17):1559–69.

23.   West J, Card TR, Aithal GP, Fleming KM. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study. Aliment Pharmacol Ther 2017;45(7):983–90.

24.   Huang DQ, Tran S, Barnett S, Zou B, Yeo YH, Cheung R, et al. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study. Hepatol Int 2024;18(2):540–9.

25.   Reddy KR, McLerran D, Marsh T, Parikh N, Roberts LR, Schwartz M, et al. Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study. Gastroenterology 2023;165(4):1053-1063.e6.

26.   Bengtsson B, Widman L, Wahlin S, Stål P, Björkström NK, Hagström H. The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: A Swedish nationwide population-based cohort study. United Eur Gastroenterol J 2022;10(5):465–76.

27.   Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, et al. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. Clin Gastroenterol Hepatol 2022;20(2):283-292.e10.

28.   Fleming KM, Aithal GP, Card TR, West J. All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int 2012;32(1):79–84.

29.   Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010;52(1):132–41.

30.   Davyduke T, Tandon P, Al-Karaghouli M, Abraldes JG, Ma MM. Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care. Hepatol Commun 2019;3(10):1322.

31.   Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2009;7(10):1104–12.

32.   Jones KC, Weatherly H, Birch S, Castelli A, Chalkley M, Dargan A, et al. Unit Costs of Health and Social Care 2023 Manual [Internet]. Kent, UK: Personal Social Services Research Unit (University of Kent); 2024 [cited 2024 Dec 20]. Available from: https://doi.org/10.22024/UniKent/01.02.105685

33. NHS England. 2023/24 National Cost Collection Data for the NHS [Internet]. 2024 [cited 2024 Dec 20];Available from: https://www.england.nhs.uk/publication/2023-24-national-cost-collection-data-publication/

34. Cullen K, Jones M, Pockett RD, Burton A, Cross TJS, Rowe IA, et al. Cost of hepatocellular carcinoma to the national health service in England: a registry-based analysis. BMJ Open Gastroenterol 2023;10(1):e000998.

35. Hernandez M, Pudney S, Wailoo A. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from an English population study [Internet]. The University of Sheffield; 2020 [cited 2024 Dec 20]. Available from: https://orda.shef.ac.uk/articles/report/Estimating_the_relationship_between_EQ-5D-5L_and_EQ-5D-3L_results_from_an_English_population_study/25219157/1

36. Hernández Alava M, Pudney S, Wailoo A. Estimating EQ-5D by age and sex for the UK [Internet]. NICE Decision Suport Unit; 2022 [cited 2024 Dec 20]. Available from: https://www.sheffield.ac.uk/nice-dsu/methods-development/estimating-eq-5d

37. Verma M, Paik JM, Younossi I, Tan D, Abdelaal H, Younossi ZM. The impact of hepatocellular carcinoma diagnosis on patients' health-related quality of life. Cancer Med 2021;10(18):6273–81.

38. Ara R, Brazier J. Deriving an Algorithm to Convert the Eight Mean SF-36 Dimension Scores into a Mean EQ-5D Preference-Based Score from Published Studies (Where Patient Level Data Are Not Available). Value Health 2008;11(7):1131–43.

39. Jones KC, Weatherly H, Birch S, Castelli A, Chalkley M, Dargan A, et al. Unit Costs of Health and Social Care 2024 Manual [Internet]. Kent, UK: Personal Social Services Research Unit (University of Kent) & Centre for Health Economics (University of York); 2025 [cited 2025 Apr 12]. Available from: https://www.pssru.ac.uk/unitcostsreport/

40. Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Gastroenterology 2018;154(5):1369–79.

41. Salavrakos M, Piessevaux H, Komuta M, Lanthier N, Stärkel P. Fibroscan Reliably Rules Out Advanced Liver Fibrosis and Significant Portal Hypertension in Alcoholic Patients. J Clin Gastroenterol 2019;53(10):772.

42. Nahon P, Kettaneh A, Tengher-Barna I, Ziol M, Lédinghen V de, Douvin C, et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008;49(6):1062–8.

43. Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 2022;71(5):1006–19.

44. Chowdhury AB, Mehta KJ. Liver biopsy for assessment of chronic liver diseases: a synopsis. Clin Exp Med 2023;23(2):273–85.

45. Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet 2019;393(10181):1597–608.

46. Forlano R, Stanic T, Jayawardana S, Mullish BH, Yee M, Mossialos E, et al. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies. Liver Int 2024;44(1):61–71.

47. Tanajewski L, Harris R, Harman DJ, Aithal GP, Card TR, Gkountouras G, et al. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. BMJ Open 2017;7(6):e015659.

48. Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med 2017;177(5):633–40.

49.   Tan Y, Zhen Q, Ding X, Shen T, Liu F, Wang Y, et al. Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes. Front Endocrinol [Internet] 2022 [cited 2025 Mar 7];13. Available from: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.935180/full

50.   Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 2021;384(12):1113–24.

51.   Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 2023;29(11):2919–28.

52.   Srivastava A, Jong S, Gola A, Gailer R, Morgan S, Sennett K, et al. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol 2019;19(1):122.

53.   Crossan C, Majumdar A, Srivastava A, Thorburn D, Rosenberg W, Pinzani M, et al. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis. Liver Int 2019;39(11):2052–60.

54.   Asphaug L, Thiele M, Krag A, Melberg HO, Consortium on behalf of the G. Cost-Effectiveness of Noninvasive Screening for Alcohol-Related Liver Fibrosis. Hepatology 2020;71(6):2093.